ID   A2780/CP70
AC   CVCL_0135
SY   A2780/cp70; A2780 CP70; A2780(CP70); A2780CP70; A2780/CP; A2780-CP; A2780-cp; A 2780 CP; A2780CP; 2780CP; CP70; CP-70
DR   BTO; BTO_0003845
DR   MCCL; MCC:0000028
DR   cancercelllines; CVCL_0135
DR   GEO; GSM184400
DR   GEO; GSM184401
DR   GEO; GSM743511
DR   GEO; GSM851908
DR   GEO; GSM1178064
DR   GEO; GSM1178065
DR   NCBI_Iran; C454
DR   PRIDE; PXD003668
DR   Progenetix; CVCL_0135
DR   Wikidata; Q54606604
RX   PubMed=1348364;
RX   PubMed=1999494;
RX   PubMed=2429947;
RX   PubMed=3335022;
RX   PubMed=3539322;
RX   PubMed=7954422;
RX   PubMed=9554442;
RX   PubMed=12080474;
RX   PubMed=17254797;
RX   PubMed=19926575;
RX   PubMed=27561551;
RX   PubMed=28196595;
RX   PubMed=28546799;
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; HGNC:795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu365Lys (c.1093G>A); ClinVar=VCV000419222; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:17271; RRAS2; Simple; p.Gln72Leu (c.215A>T); ClinVar=VCV000009447; Zygosity=Homozygous (from parent cell line).
CC   Omics: Glycomics; N-glycan profiling; Lectin array.
CC   Omics: Proteomics.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): PubMed=17254797
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 13
ST   D16S539: 11,13
ST   D18S51: 16,18
ST   D21S11: 27,28
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 15,17
ST   FGA: 19,24
ST   TH01: 6
ST   TPOX: 8,10
ST   vWA: 15,16
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 30
//
RX   PubMed=28546799; DOI=10.1186/s12014-017-9155-z; PMCID=PMC5442857;
RA   Zhao, Ran
RA   Qin, Wen-Jun
RA   Qin, Rui-Huan
RA   Han, Jing
RA   Li, Can
RA   Wang, Yi-Sheng
RA   Xu, Cong-Jian
RT   "Lectin array and glycogene expression analyses of ovarian cancer cell
RT   line A2780 and its cisplatin-resistant derivate cell line A2780-cp.";
RL   Clin. Proteomics 14:20.1-20.10(2017).
//
RX   PubMed=3539322;
RA   Behrens, Brent C.
RA   Hamilton, Thomas C.
RA   Masuda, Hidetaka
RA   Grotzinger, Karen R.
RA   Whang-Peng, Jacqueline
RA   Louie, Karen Guigere
RA   Knutsen, Turid
RA   McKoy, Wilma M.
RA   Young, Robert C.
RA   Ozols, Robert F.
RT   "Characterization of a cis-diamminedichloroplatinum(II)-resistant
RT   human ovarian cancer cell line and its use in evaluation of platinum
RT   analogues.";
RL   Cancer Res. 47:414-418(1987).
//
RX   PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001;
RA   Azari, Shahram
RA   Ahmadi, Nahid
RA   Jeddi-Tehrani, Mahmood
RA   Shokri, Fazel
RT   "Profiling and authentication of human cell lines using short tandem
RT   repeat (STR) loci: report from the National Cell Bank of Iran.";
RL   Biologicals 35:195-202(2007).
//
RX   PubMed=2429947; DOI=10.20772/cancersci1985.77.9_941;
RA   Tsuruo, Takashi
RA   Hamilton, Thomas C.
RA   Louie, Karen Guigere
RA   Behrens, Brent C.
RA   Young, Robert C.
RA   Ozols, Robert F.
RT   "Collateral susceptibility of adriamycin-, melphalan- and
RT   cisplatin-resistant human ovarian tumor cells to bleomycin.";
RL   Jpn. J. Cancer Res. 77:941-945(1986).
//
RX   PubMed=19926575; DOI=10.1309/AJCPTK87EMMIKPFS; PMCID=PMC3040237;
RA   DeRycke, Melissa S.
RA   Andersen, John D.
RA   Harrington, Katherine M.
RA   Pambuccian, Stefan Eduard
RA   Kalloger, Steve E.
RA   Boylan, Kristin L.M.
RA   Argenta, Peter Alexander
RA   Skubitz, Amy Patrice Norden
RT   "S100A1 expression in ovarian and endometrial endometrioid carcinomas
RT   is a prognostic indicator of relapse-free survival.";
RL   Am. J. Clin. Pathol. 132:846-856(2009).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li, Jun
RA   Zhao, Wei
RA   Akbani, Rehan
RA   Liu, Wen-Bin
RA   Ju, Zhen-Lin
RA   Ling, Shi-Yun
RA   Vellano, Christopher P.
RA   Roebuck, Paul
RA   Yu, Qing-Hua
RA   Eterovic, Agda Karina
RA   Byers, Lauren Averett
RA   Davies, Michael A.
RA   Deng, Wan-Leng
RA   Gopal, Y.N. Vashisht
RA   Chen, Guo
RA   von Euw, Erika Maria
RA   Slamon, Dennis Joseph
RA   Conklin, Dylan
RA   Heymach, John Victor
RA   Gazdar, Adi F.
RA   Minna, John D.
RA   Myers, Jeffrey N.
RA   Lu, Yi-Ling
RA   Mills, Gordon B.
RA   Liang, Han
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=1348364; DOI=10.1073/pnas.89.7.3070; PMCID=PMC48805;
RA   Godwin, Andrew Kent
RA   Meister, Alton
RA   O'Dwyer, Peter J.
RA   Huang, Chin-Shiou
RA   Hamilton, Thomas C.
RA   Anderson, Mary E.
RT   "High resistance to cisplatin in human ovarian cancer cell lines is
RT   associated with marked increase of glutathione synthesis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992).
//
RX   PubMed=12080474; DOI=10.1038/sj.onc.1205542;
RA   Manzano, Ramon G.
RA   Montuenga, Luis M.
RA   Dayton, Mark A.
RA   Dent, Paul
RA   Kinoshita, Ichiro
RA   Vicent, Silvestre
RA   Gardner, Ginger J.
RA   Nguyen, PhuongMai
RA   Choi, Yung-Hyun
RA   Trepel, Jane B.
RA   Auersperg, Nelly
RA   Birrer, Michael J.
RT   "CL100 expression is down-regulated in advanced epithelial ovarian
RT   cancer and its re-expression decreases its malignant potential.";
RL   Oncogene 21:4435-4447(2002).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645; PMCID=PMC5007461;
RA   Coscia, Fabian
RA   Watters, Karen M.
RA   Curtis, Marion
RA   Eckert, Mark A.
RA   Chiang, Chun-Yi
RA   Tyanova, Stefka
RA   Montag, Anthony
RA   Lastra, Ricardo R.
RA   Lengyel, Ernst Robert
RA   Mann, Matthias
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//
RX   PubMed=7954422;
RA   Johnson, Steven W.
RA   Swiggard, Pamela A.
RA   Handel, Laura M.
RA   Brennan, James M.
RA   Godwin, Andrew Kent
RA   Ozols, Robert F.
RA   Hamilton, Thomas C.
RT   "Relationship between platinum-DNA adduct formation and removal and
RT   cisplatin cytotoxicity in cisplatin-sensitive and -resistant human
RT   ovarian cancer cells.";
RL   Cancer Res. 54:5911-5916(1994).
//
RX   PubMed=3335022;
RA   Alley, Michael Curtis
RA   Scudiero, Dominic A.
RA   Monks, Anne
RA   Hursey, Miriam L.
RA   Czerwinski, Maciej J.
RA   Fine, Donald L.
RA   Abbott, Betty Jane
RA   Mayo, Joseph G.
RA   Shoemaker, Robert H.
RA   Boyd, Michael R.
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=1999494; DOI=10.1172/JCI115080; PMCID=PMC329864;
RA   Parker, Ricardo J.
RA   Eastman, Alan
RA   Bostick-Bruton, Frieda
RA   Reed, Eddie
RT   "Acquired cisplatin resistance in human ovarian cancer cells is
RT   associated with enhanced repair of cisplatin-DNA lesions and reduced
RT   drug accumulation.";
RL   J. Clin. Invest. 87:772-777(1991).
//
RX   PubMed=9554442; DOI=10.1093/jnci/90.8.597;
RA   Sabichi, Anita Lyn
RA   Hendricks, Denver T.
RA   Bober, Mary A.
RA   Birrer, Michael J.
RT   "Retinoic acid receptor beta expression and growth inhibition of
RT   gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl)
RT   retinamide.";
RL   J. Natl. Cancer Inst. 90:597-605(1998).
//